Long QT Syndrome (LQTS) Market Research 2024 Featuring Thryv Therapeutics and Vertex: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access

Core Insights - The report provides a comprehensive assessment of the Long QT Syndrome (LQTS) market, focusing on epidemiology, treatment landscape, unmet needs, emerging therapies, and value and access [2][3][4] Disease Overview - LQTS is identified as a rare congenital cardiac arrhythmia characterized by prolonged recovery in cardiac action potential, which can lead to fatal arrhythmias [3] Epidemiology - The report includes an analysis of the prevalence and incidence of LQTS in the US and EU5, detailing diagnosed and drug-treated cases [5][6] Current Treatment - The standard treatment for LQTS is beta blockers, which effectively manage most cases, particularly LQTS type 1, despite side effects such as fatigue and depression [4] - Surgical options like implantable cardioverter-defibrillators (ICDs) and left cardiac sympathetic denervation (LCSD) are considered for high-risk patients who do not respond to beta blockers [4][7] Unmet Needs - There is a significant need for additional pharmaceutical treatments to reduce reliance on surgical options for refractory patients, as many patients experience side effects from current treatments [4][8] Pipeline Analysis - The clinical pipeline for LQTS treatments is sparse, with only one industry-sponsored drug currently in development, indicating a potential wait of five or more years for new therapies [4][5] Value and Access - The report reviews the evidence required to communicate the value of treatments to stakeholders, including providers and payers, and compares treatment pricing in the U.S. [8]